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Abstract
Objective
The adenoma detection rate (ADR) varies widely between physicians, possibly due to
patient population differences, hampering direct ADR comparison. We developed and vali-
dated a prediction model for adenoma detection in an effort to determine if physicians’
ADRs should be adjusted for patient-related factors.
Materials and methods
Screening and surveillance colonoscopy data from the cross-sectional multicenter cluster-
randomized Endoscopic Quality Improvement Program-3 (EQUIP-3) study (NCT02325635)
was used. The dataset was split into two cohorts based on center. A prediction model for
detection of1 adenoma was developed using multivariable logistic regression and subse-
quently internally (bootstrap resampling) and geographically validated. We compared pre-
dicted to observed ADRs.
Results
The derivation (5 centers, 35 physicians, overall-ADR: 36%) and validation (4 centers, 31
physicians, overall-ADR: 40%) cohort included respectively 9934 and 10034 patients (both
cohorts: 48% male, median age 60 years). Independent predictors for detection of1 ade-
noma were: age (optimism-corrected odds ratio (OR): 1.02; 95%-confidence interval (CI):
1.02–1.03), male sex (OR: 1.73; 95%-CI: 1.60–1.88), body mass index (OR: 1.02; 95%-CI:
1.01–1.03), American Society of Anesthesiology physical status class (OR class II vs. I:
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1.29; 95%-CI: 1.17–1.43, OR classIII vs. I: 1.57; 95%-CI: 1.32–1.86), surveillance versus
screening (OR: 1.39; 95%-CI: 1.27–1.53), and Hispanic or Latino ethnicity (OR: 1.13; 95%-
CI: 1.00–1.27). The model’s discriminative ability was modest (C-statistic in the derivation:
0.63 and validation cohort: 0.60). The observed ADR was considerably lower than predicted
for 12/66 (18.2%) physicians and 2/9 (22.2%) centers, and considerably higher than pre-
dicted for 18/66 (27.3%) physicians and 4/9 (44.4%) centers.
Conclusion
The substantial variation in ADRs could only partially be explained by patient-related factors.
These data suggest that ADR variation could likely also be due to other factors, e.g. physi-
cian or technical issues.
Introduction
Colonoscopy combined with polypectomy, when necessary, has been shown to decrease colo-
rectal cancer (CRC) incidence[1] and CRC-related mortality.[1,2] However, the protective
benefit is reduced by the occurrence of interval-CRC, i.e. CRC occurring within the colonos-
copy surveillance interval. Three main reasons for the occurrence of interval-CRC have been
suggested in literature, namely: 1) missed lesions during colonoscopy (accounting for approxi-
mately 50–60% of the cases), 2) incomplete resection, and 3) newly developed cancers.[3] The
proportion of patients undergoing colonoscopy in which at least one adenoma is detected, the
adenoma detection rate (ADR), has been shown to be inversely associated with the develop-
ment of interval-CRC.[4,5] Quality improvement in colonoscopy therefore aims, among other
things, at increasing and thereby achieving sufficient physicians’ ADRs. American and Euro-
pean guidelines recommend thus ADRs to be25%,[6,7] i.e.30% in male and20% in
female patients.[7]
The influence of several modifiable factors, such as procedural and technological factors, on
ADR have been studied.[8] Moreover, training programs to improve the ADR have been
developed and evaluated.[9,10] Nevertheless, ADRs vary widely between physicians,[11] possi-
bly caused by patient population differences. ADR comparison between centers and physicians
is therefore challenging and even more complicated by the strict domain in which the ADR
should be calculated, i.e. for patients at average risk of adenoma detection in a screening popu-
lation. Average risk individuals are those without additional risk factors for adenoma detec-
tion, e.g. a family history of CRC, a personal history of CRC or colorectal adenomas, and are
not preselected for colonoscopy through, for example, stool tests, e.g. fecal immunochemical
tests, or other diagnostic tests. Several initiatives aim to provide physicians with feedback on
their ADR through online databases, such as the Gastro-Intestinal Quality Improvement Con-
sortium (GIQuIC).[12] The feedback could be improved if next to these unadjusted ADRs the
expected ADR for a physician’s patient population could be predicted.
Several prediction models based on patient risk factors have been developed for the detec-
tion of advanced adenomas[13–23] and a few for any adenoma.[18,20,23–25] Most of the
models for any adenoma detection were developed in Asian populations,[18,20,23,24] with a
generally lower adenoma prevalence than Western populations, had a moderate discriminative
ability, and only included screening colonoscopies.[18,20,23–25]Application of these models
is thus hampered in a Western setting and in day-to-day practice where screening and
Prediction of adenoma detection rates during screening and surveillance colonoscopy
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surveillance colonoscopies might both be used for ADR calculations as they are performed
side-to-side.
Therefore, the aim of the present study was to develop and validate a prediction model for
colorectal adenoma detection based on patient risk factors in a screening and surveillance pop-
ulation. The secondary aim was to compare the observed individual physicians’ and centers’
ADRs to the predicted proportion of patients with1 adenoma based on the developed
model.
Materials and methods
The present study has been performed and reported according to the TRIPOD statement for
the reporting of multivariable prediction models (S2 File).[26]
Data source
We used the data from the cluster-randomized cross-sectional Endoscopic Quality Improve-
ment Program-3 (EQUIP-3) study (Clinical Trials Registration: NCT02325635) that ran from
September 2013 until January 2015.[9] The EQUIP-3 study was approved by the Mayo Clinic
Institutional Review Board and was considered minimal risk and exempt from patient-level
consent.[9] In the EQUIP-3 study centers were randomized, after a lead-in phase, to receive a
quality improvement program aimed at increasing the ADR or no intervention. During the
lead-in phase data on all colonoscopies performed in all participating centers was collected
enabling analyses of the colonoscopy quality metrics without the influence of the quality
improvement program. The centers randomized to receive the quality improvement program,
received the first EQUIP training as described in the EQUIP-1 study,[27] consisting of baseline
measurement of ADR, followed by an in-person 1-hour powerpoint based training emphasiz-
ing on improvement of adenoma detection and flat lesion recognition. Furthermore in these
centers posters about EQUIP were placed in each endoscopy room, and the ADR of all endos-
copists was one-on-one discussed, typically with low performers. Each center and individual
then received regular follow-up ADR reports, approximately monthly during the post-inter-
vention phase.[9] Data was collected through the GIQuIC-form (S1 File)[12] by the physician
or nurse at the end of the procedure. Pathology results were entered subsequently when avail-
able. Predictor assessment was thus blinded for the outcome.
Sample split
The original dataset was split into two cohorts based on the performing center. This enabled
validation of the model in geographically different centers, which is a second-best after fully
external validation. In short, in the first cohort, i.e. the derivation cohort, the model will be
developed and internally validated. Subsequently, the fitted model will be geographically vali-
dated in the second cohort, i.e. the validation cohort. The number of patients, centers, physi-
cians, and randomization to the intervention were balanced between the derivation and
validation cohort.
Participants
Sixty-six physicians from nine centers in the United States, i.e. within California, Illinois, Indi-
ana, New Mexico, New York, Ohio, Tennessee, and Virginia, participated. Patients undergoing
outpatient colonoscopy were included in the EQUIP-3 study if 1) they did not have a history
of colorectal surgery; 2) indication for colonoscopy was screening or surveillance, as indicated
Prediction of adenoma detection rates during screening and surveillance colonoscopy
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in the GIQuIC database; and 3) bowel preparation was adequate, i.e. sufficient to accurately
detect polyps6 mm.
In the present study we excluded patients: 1) <50 years, because screening is recommended
50 years; 2) with a known increased risk of colorectal neoplasia who are normally discarded
in ADR calculations, i.e. colonoscopy for a high-risk genetic CRC syndrome or surveillance
colonoscopy because of inflammatory bowel disease; and 3) a personal history of CRC, because
these patients will probably have undergone colorectal surgery. Screening and surveillance
colonoscopies were both included, because these are performed side-to-side in daily practice
and might both be used in ADR calculations. Furthermore, a prediction model for adenoma
detection in both a screening and surveillance population potentially facilitates ADR compari-
sons across physicians and centers in both screening and surveillance settings.
A minuscule proportion (N = 53, 0.2%) of colonoscopies were probably performed in a
patient already included in the study, we therefore excluded these second colonoscopies from
the database.
Outcome
The outcome of the prediction model was the detection of1 histologically confirmed colo-
rectal adenoma per patient. The histological assessment was performed in daily practice, and
thus not completely blinded for patient factors, e.g. sex and age of the patient. However, the
pathologist did not have access to the GIQuIC form and was consequently blinded to factors
such as BMI, ASA class, and race and ethnicity, and it is therefore unlikely that these factors
could have influenced the pathologists’ judgment.
Predictors for adenoma detection
Pre-colonoscopic possible predictors for adenoma detection were selected based on previously
published prediction models for the detection of (advanced) adenomas.[13–25]
Age and body mass index (BMI) in kg/m2 were analyzed as continuous variables. We cate-
gorized race as: “African-American”, “Asian”, “other” (due to the small numbers of patients
per subgroup including white, native American, Alaska native, native Hawaiian, native Pacific
and patients categorized as other), and “unknown or patient declined to provide”. Ethnicity
was categorized as: “Hispanic or Latino”, “not Hispanic or Latino”, and “unknown or patient
declined to provide”.
As a proxy for clinical condition and co-morbidities the American Society of Anesthesiol-
ogy physical status (ASA) was used[28]. Because no ASA V patients and only a small number
of ASA IV patients were included, we categorized this variable as: “ASA I”, “ASA II” and “ASA
III or IV”.
The indication of colonoscopy was surveillance, i.e. a personal history of colorectal adeno-
mas or surveillance marked as indication on the GIQuIC form, or colorectal cancer screening.
Family history, i.e.1 first-degree relative<60 years diagnosed with the condition, of colorec-
tal adenomas and family history of CRC were analyzed as dichotomous variables. The pre-
colonoscopic risk on adenoma detection, i.e. high or low, was not included as a possible pre-
dictor due to possible multicollinearity with indication, family history of CRC and family his-
tory of colorectal adenomas.
Statistical analysis
All statistical analyses were performed with R language environment for statistical computing
version 3.1.3.[29]
Prediction of adenoma detection rates during screening and surveillance colonoscopy
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Sample size. We refer to the original paper for sample size calculations.[9] The number of
patients with1 adenoma detected exceeded ten per possible predictor considered, and
should therefore be sufficient for the analysis.
Missing data. To correct for possible errors with data-entry on the GIQuIC-form we
recoded the following implausible values as missing: BMI <15 or >55kg/m2, height<140 or
>220cm, weight <40 or >250kg. We assumed missing data of these variables to be missing at
random, in other words the fact that the data is missing is not related to the value that is miss-
ing.[30] Multiple imputation based on iterative (10 iterations) chained equations with predic-
tive mean matching was performed, creating 20 multiple imputed datasets, using the MICE-
package for R.[31] The multiple imputation procedure was performed based on center, physi-
cian, all possible predictors and detection of:1 adenoma,3 adenomas, any polyp, advanced
adenoma(s), adenocarcinoma(s), and serrated lesion(s).[32] The imputed values for BMI were
calculated from the imputed height and weight.
We assumed patient’s race and ethnicity being categorized as “unknown or patient declined
to provide” to be missing not at random, i.e. we expect that there is a reason why these values
are not filled out in the GIQuIC database, and we therefore retained this category in the
modeling process.
Descriptive statistics. The number of patients per center and per physician is presented
as medians and ranges. Continuous baseline characteristics are presented as mean ± standard
deviation, and categorical data as frequencies with proportions. The proportion of patients
with1 adenoma detected, i.e. the ADR, is reported per subgroup.
Univariable odds ratios (ORs) including 95%-confidence intervals (CIs) for the detection of
1 adenoma were estimated for all possible predictors based on logistic regression modeling.
An odds ratio was regarded statistically significant if the 95%-CI did not include ‘one’.
Model development and internal validation within the derivation cohort. A multivari-
able logistic regression model with detection of1 adenoma as outcome was fitted with the
following possible predictors: age, sex, BMI, race, ethnicity, ASA class, indication, family his-
tory of CRC, family history of colorectal adenomas, interaction between race and sex, and
interaction between ethnicity and sex. The model estimates were adjusted for randomization
to a quality improvement intervention by adding the dichotomous variable “colonoscopy per-
formed after intervention received versus no intervention received” to the model. The final
model was selected using stepwise backwards selection based on Akaike’s information
criterion.
The model’s discriminative ability was assessed with the apparent C-statistic, which is
equivalent to the area under the receiver operating characteristic curve. Subsequently internal
validation was performed using 1000 bootstrap resamples per imputed dataset to calculate the
shrinkage factor and optimism-corrected C-statistic. Regular bootstrap resampling without
taking clustering into account was performed.[33] The optimism-corrected model coefficients
and intercept were calculated based on the shrinkage factor. The model calibration was visually
assessed with a calibration plot.
Geographical validation and model-update within the validation cohort. Because we
expected differences in the baseline adenoma prevalence and overall effect of predictors due
to geographic variation we performed logistic re-calibration by fitting a logistic regression
model with the original model’s linear predictor as the independent variable and detection of
1 adenoma as the dependent variable. The intercept and coefficient of this new logistic
model are the re-calibrated intercept and slope-correction, respectively.[34] The discrimina-
tive ability (C-statistic) and calibration (with a calibration plot) of the updated model were
assessed.
Prediction of adenoma detection rates during screening and surveillance colonoscopy
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Predicted proportion of patient with1 adenoma detected compared to
actual ADRs
In both cohorts the probability for the detection of1 adenoma per patient was predicted
with the final model. The sum of the predicted probabilities of adenoma detection per patient
was calculated resulting in the predicted proportion of patients with1 adenoma per physi-
cian and center. These predicted proportions were graphically compared to the physicans’ and
centers’ observed ADR, i.e. the proportion of patients with1 adenoma detected, including
95% Wilson CIs. The observed ADR was considered considerably lower than predicted if the
upper bound of the 95% CI was lower than the predicted ADR, and considerably higher than
predicted if the lower bound of the 95% CI was higher than the predicted ADR.
Results
Study population
The 22316 patients were divided between the derivation and validation cohort. In the deriva-
tion cohort 9934 patients (1223 patients were excluded) were examined by 35 physicians in
five centers (Fig 1). In the validation cohort 10034 patients (1125 patients were excluded) were
examined by 31 physicians in four centers.
Missing values
No outcome data were missing. A substantial proportion (28.2–35.1%) of patients had missing
values for height, weight or BMI (Fig 1).
Baseline characteristics and ADR per subgroup of patients
The provider and patient characteristics, and ADR per variable are summarized in Table 1.
The reasons for being at high risk of adenoma detection are summarized in S1 Table. Within
the derivation cohort the mean age was 60.2 years, 47.6% were male, and the mean BMI was
28.3 kg/m2. The overall ADR was 35.9%, with ADRs for female (29.6%) and male (42.9%)
patients above the recommended thresholds[7] of20% and30% respectively. Within the
validation cohort the patients were slightly older (mean age 61.0 years), almost the same pro-
portion was male (47.8%), and patients had a higher mean BMI (29.2 kg/m2). The overall ADR
(40.0%) was higher, and again the ADR for female (34.9%) and male (45.6%) patients was
above the recommended thresholds[7].
Regarding the baseline characteristics the derivation and validation cohort differed the
most with respect to the included proportion of African-American and Hispanic or Latino
patients, and colonoscopies with screening as indication (Table 1).
Univariable association between predictors and detection of1
adenoma
In the derivation cohort statistically significant positive predictors for detection of1 ade-
noma were age (per year increase), male sex, BMI (per kg/m2 increase), ASA class II compared
to class I, ASA class III or IV compared to I, Hispanic or Latino ethnicity and surveillance
compared to screening as indication (Table 2).
Some univariable associations within the validation cohort clearly differed from those
observed in the derivation cohort. The OR of ASA class III or IV compared to I was lower and
statistically non-significant. The OR of family history of CRC was above 1 in the validation
cohort, but was still non-significant. The OR for African-American, Asian, and Hispanic or
Prediction of adenoma detection rates during screening and surveillance colonoscopy
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Fig 1. Flowchart of patients in the derivation and validation cohort with an overview of the reasons for and number of excluded patients and
number of implausible and missing values. BMI, body mass index; CRC, colorectal cancer; EQUIP-3, Endoscopic Quality Improvement Program-3
study; IBD, inflammatory bowel disease; N, number of patients.
https://doi.org/10.1371/journal.pone.0185560.g001
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Table 1. Provider and patient characteristics for the derivation and validation cohort and the adenoma detection rate per patient subgroup.
Derivation cohort Validation cohort
All patients
[N = 9934]
N (%)a
Patients with1 adenoma
[N = 3568]
N (ADR)a
All patients
[N = 10034]
N (%)a
Patients with1 adenoma
[N = 4013]
N (ADR)a
Provider characteristics
Centerb, median N (range) 1544 (1144–3336) 537 (431–1232) 2492.5 (1228–3821) 735 (561–1982)
Physicianc, median N (range) 289 (55–725) 93 (11–306) 246 (57–812) 96 (12–330)
Patient characteristics
Age in years, mean ± SD 60.2 ± 7.7 61.3 ± 7.8 61.0 ± 8.2 61.8 ± 8.3
Female 5209 (52.4) 1542 (29.6) 5237 (52.2) 1826 (34.9)
Male 4725 (47.6) 2026 (42.9) 4797 (47.8) 2187 (45.6)
BMI in kg/m2, mean ± SD 28.3 ± 5.6
[N = 6851]d
28.8 ± 5.5
[N = 2538]d
29.2 ± 5.8
[N = 6511]d
29.7 ± 5.8
[N = 3120]d
ASA I 2689 (27.1) 793 (29.5) 1920 (19.1) 668 (34.8)
ASA II 6455 (65.0) 2420 (37.5) 7532 (75.1) 3119 (41.4)
ASA III or IVe 790 (8.0) 355 (44.9) 582 (5.8) 226 (38.8)
Race
Otherf 6368 (64.1) 2250 (35.3) 8306 (82.8) 3463 (41.7)
African-American or black 1320 (13.3) 477 (36.1) 701 (7.0) 263 (37.5)
Asian 134 (1.3) 49 (36.6) 149 (1.5) 51 (34.2)
Unknown or patient declined to
provide
2112 (21.3) 792 (37.5) 878 (8.8) 236 (26.9)
Ethnicity
Not Hispanic or Latino 5933 (59.7) 2067 (34.8) 8451 (84.2) 3517 (41.6)
Hispanic or Latino 1415 (14.2) 533 (37.7) 87 (0.9) 31 (35.6)
Unknown or patient declined to
provide
2586 (26.0) 968 (37.4) 1496 (14.9) 465 (31.1)
Indication for colonoscopyg
Screening 7353 (74.0) 2409 (32.8) 6518 (65.0) 2361 (36.2)
Surveillance 2581 (26.0) 1159 (44.9) 3516 (35.0) 1652(47.0)
Risk assessmenth
Average risk 6558 (66.0) 2168 (33.1) 6589 (65.7) 2452 (37.2)
High risk 3376 (34.0) 1400 (41.5) 3445 (34.3) 1561 (45.3)
ADR, adenoma detection rate, i.e. proportion of patients with1 adenoma detected per subgroup; ASA, American Society of Anesthesiology physical
status class; BMI, body mass index; N, number of patients; SD, standard deviation.
aUnless, stated otherwise in the beginning of the row.
bFive centers were included in the derivation cohort, and four centers in the validation cohort.
cThirty-five physicians were included in the derivation cohort, and thirty-one physicians were included in the validation cohort.
dNumber of patients without missing values.
eOnly three patients in the development cohort and no patients in the validation cohort were in ASA category IV and therefore ASA III and IV were
combined.
fIncluding white, native American, Alaska native, native Hawaiian, native Pacific patients and patient’s race categorized as other.
gThe indication is considered surveillance for patients with a personal history of colorectal adenomas or surveillance marked as indication on the
GastroIntestinal Quality Improvement Consortium (GIQuIC) form.
hThe number of patients categorized per reason for high risk of adenoma detection are displayed in supporting information Table 1 (S1 Table).
https://doi.org/10.1371/journal.pone.0185560.t001
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Latino patients was <1 within the validation cohort, while these variables had an OR>1 in the
derivation cohort.
Model development and validation within the derivation cohort
After stepwise backwards selection the following patient-related predictors were selected in the
multivariable model (Table 3): age, sex, BMI, ASA class, indication (surveillance versus screen-
ing), and Hispanic or Latino ethnicity. The discriminative ability was modest (apparent C-sta-
tistic: 0.630 and optimism-adjusted C-statistic: 0.626). Calibration of the model was visually
Table 2. Univariable odds ratios of possible risk factors for the detection of1 adenoma within the derivation and validation cohort.
Possible predictors Derivation cohort Validation cohort
Univariable odds ratioa
[95%-CI]
Univariable odds ratioa
[95%-CI]
Age (per year increase) 1.03 [1.02–1.04] 1.02 [1.02–1.03]
Female 1.00 (ref) 1.00 (ref)
Male 1.79 [1.64–1.94] 1.57 [1.44–1.70]
BMI (per kg/m2 increase)b 1.02 [1.01–1.03] 1.03 [1.02–1.04]
ASA I 1.00 (ref) 1.00 (ref)
ASA II 1.43 [1.30–1.58] 1.32 [1.19–1.47]
ASA III or IVc 1.95 [1.66–2.30] 1.19 [0.98–1.44]
Race
Otherd 1.00 (ref) 1.00 (ref)
African-American or black 1.04 [0.91–1.17] 0.84 [0.72–0.98]
Asian 1.06 [0.73–1.50] 0.73 [0.51–1.02]
Unknown or patient declined to provide 1.10 [0.99–1.22] 0.51 [0.44–0.60]
Ethnicity
Not Hispanic or Latino 1.00 (ref) 1.00 (ref)
Hispanic or Latino 1.13 [1.00–1.27] 0.78 [0.49–1.20]
Unknown or patient declined to provide 1.12 [1.02–1.23] 0.63 [0.56–0.71]
Indication for colonoscopye
Screening 1.00 (ref) 1.00 (ref)
Surveillance 1.67 [1.53–1.83] 1.56 [1.44–1.70]
History of colorectal cancer
No 1.00 (ref) 1.00 (ref)
Familyf 0.88 [0.75–1.02] 1.13 [0.97–1.31]
History of colorectal adenomas
No 1.00 (ref) 1.00 (ref)
Familyf 1.12 [0.93–1.35] 1.17 [0.88–1.55]
ASA, American Society of Anesthesiology physical status class; BMI, body mass index; CI, confidence interval; ref, reference category.
aOdds ratios based on a univariable logistic regression model with detection of1 adenoma as outcome. 95% confidence intervals are profiled confidence
intervals.
bThis association is calculated after multiple imputation.
cOnly three patients in the development cohort and no patients in the validation cohort were in ASA category IV and therefore ASA III and IV were
combined.
dIncluding white, native American, Alaska native, native Hawaiian and native Pacific patients and patient’s race categorized as other.
eThe indication is considered surveillance for patients with a personal history of colorectal adenomas or surveillance marked as indication on the
GastroIntestinal Quality Improvement Consortium (GIQuIC) form.
fFamily history is defined as a first degree relative diagnosed with the condition at an age <60 years.
https://doi.org/10.1371/journal.pone.0185560.t002
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accurate, however, the model overestimated the probability of the detection of1 adenoma
among patients with a low observed and especially high observed adenoma detection (Fig 2A).
Geographical validation within the validation cohort
The re-calibrated model with an intercept of -2.406 and overall slope correction of 0.757 (final
model estimates not shown) had a modest discriminative ability (C-statistic 0.603). The model
tended to overestimate the adenoma detection among patients with a high observed adenoma
detection (Fig 2B).
Predicted proportion of patients with1 adenoma compared to
observed ADR
Within the derivation cohort the median observed ADR was 35.2% (range: 20.0–52.5%) per
physician and 36.9% (range: 27.9–39.5%) per center. Six physicians and no center had an ADR
below the recommended threshold[6,7] of25%. The median predicted proportion of
patients with1 adenoma was 36.7% (range: 31.0–40.2%) per physician and 36.5% (range:
35.0%-38.0%) per center. The upper bound of the 95%-CI of the observed ADR was lower
than the predicted proportion of patients with1 adenoma for five physicians and one center.
The lower bound of the 95%-CI of the observed ADR was higher than the predicted propor-
tion of patients with1 adenoma for five physicians and one center (Figs 3 and 4A).
Within the validation cohort the median observed ADR was 41.9% (range: 4.2–65.0%) per
physician and 43.4% (range: 23.5–51.9%) per center. Five physicians and one center had an
Table 3. Prediction modela for the detection of1 adenoma per patient based on multivariable logistic regression within the derivation cohort.
Factors Uncorrected multivariable
OR [95%-CI]
Correctedb β coefficients Correctedb multivariable
OR [95%-CI]
Intercept - -3.134 -
Age (per year increase) 1.02 [1.02–1.03] 0.023 1.02 [1.02–1.03]
Female 1.00 (ref) 0 (ref) 1.00 (ref)
Male 1.76 [1.62–1.92] 0.549 1.73 [1.60–1.88]
BMI (per kg/m2 increase) 1.02 [1.01–1.03] 0.017 1.02 [1.01–1.03]
ASA I 1.00 (ref) 0 (ref) 1.00 (ref)
ASA II 1.30 [1.18–1.44] 0.256 1.29 [1.17–1.43]
ASA III or IV 1.59 [1.34–1.90] 0.451 1.57 [1.32–1.86]
Ethnicity
Not Hispanic or Latino 1.00 (ref) 0 (ref) 1.00 (ref)
Hispanic or Latino 1.13 [1.00–1.28] 0.122 1.13 [1.00–1.27]
Unknown or patient declined to provide 1.16 [1.05–1.29] 0.148 1.16 [1.05–1.28]
Indication for colonoscopyc
Screening 1.00 (ref) 0 (ref) 1.00 (ref)
Surveillance 1.41 [1.28–1.55] 0.332 1.39 [1.27–1.53]
ASA, American Society of Anesthesiology physical status class; BMI, body mass index; CI, confidence interval; OR, odds ratio; ref, reference category.
aThe presented odds ratios are adjusted for EQUIP intervention (colonoscopy performed after versus no intervention received) which had an uncorrected
OR of 1.24 [95%-CI: 1.13–1.36] in the final model.
bCorrected after internal validation using bootstrap resampling with a shrinkage factor of 0.969. The intercept is additionally corrected by subtraction of the
intercept correction of -0.017.
cThe indication is considered surveillance for patients with a personal history of colorectal adenomas or surveillance marked as indication on the
GastroIntestinal Quality Improvement Consortium (GIQuIC) form.
https://doi.org/10.1371/journal.pone.0185560.t003
Prediction of adenoma detection rates during screening and surveillance colonoscopy
PLOS ONE | https://doi.org/10.1371/journal.pone.0185560 September 28, 2017 10 / 18
Fig 2. Calibration plot of the model performance A) within the derivation cohort after internal validation (figure at the left), and B) within the
validation cohort after logistic re-calibration (figure at the right). Grouped observations are grouped per decile of patients. The observed proportion of
patients with1 adenoma detected is displayed on the y-axis, and the predicted proportion of patients with1 adenoma on the x-axis. C-statistic,
concordance statistic.
https://doi.org/10.1371/journal.pone.0185560.g002
Fig 3. Observed adenoma detection rates (including 95% Wilson confidence intervals) versus predicted proportions of patients with1
adenoma per physician within the derivation cohort. The physicians are ranked in ascending order of adenoma detection rate. The numbers on the x-
axis denote the number of patients per physician.
https://doi.org/10.1371/journal.pone.0185560.g003
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observed ADR <25%. The median predicted proportion of patients with1 adenoma was
39.1% (range: 31.9–44.2%) per physician and 39.1% (range: 36.4–41.7%) per center. The upper
bound of the 95%-CI of the observed ADR was lower than the predicted proportion of patients
with1 adenoma for seven physicians and one center. The lower bound of the 95%-CI of the
observed ADR was higher than the predicted proportion of patients with1 adenoma for 13
physicians and three centers (Figs 5 and 4B).
Fig 4. A. Observed adenoma detection rates (including 95% Wilson confidence intervals) versus predicted proportions of patients with1
adenoma per center within A) the derivation cohort (figure at the left) and B) the validation cohort (figure at the right). The centers are ranked in
ascending order of adenoma detection rate. The numbers on the x-axis denote the number of patients per center.
https://doi.org/10.1371/journal.pone.0185560.g004
Fig 5. Observed adenoma detection rates (including 95% Wilson confidence intervals) versus predicted proportions of patients with1
adenoma per physician within the validation cohort. The physicians are ranked in ascending order of adenoma detection rate. The numbers on the x-
axis denote the number of patients per physician.
https://doi.org/10.1371/journal.pone.0185560.g005
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Overall, there was no obvious trend of smaller sample sizes per physician or center at the
extremes of observed ADRs. The predicted proportion of patients with1 adenoma varied
less than the observed ADR.
Model performance including physician as predictive factor
Given the moderate discriminative ability of the prediction model, a sensitivity analysis was
performed in which the performing physician was added as a variable during model develop-
ment within the derivation cohort. After stepwise backwards selection performing physician
was selected in the model and ethnicity was left out which led to a modest increase in the
apparent C-statistic from 0.630 to 0.647.
Discussion
This study shows that age, sex, BMI, ASA class, surveillance vs. screening, and a Hispanic or
Latino ethnicity are independent patient-related predictors of colorectal adenoma detection in
a screening and surveillance population. These patient risk factors only modestly account for
the variation in individual physicians’ and centers’ ADR. The final multivariable model had a
moderate discriminative ability within the derivation and validation cohort, which slightly
increased after the addition of the performing physician as predictor. The lowest observed
ADRs were lower than predicted, while the highest observed ADRs were higher than pre-
dicted. Approximately one in six physicians performed colonoscopy with an ADR below that
predicted by patient risk factors.
Our finding that increasing age is an independent predictor of adenoma detection is in line
with the recommendation to start screening colonoscopy from 50 years onwards, since ade-
noma detection increases with age.[35] The increased risk (OR: 1.73, 95%-CI: 1.60–1.88) for
adenoma detection in male versus female patients is consistent with the current recommended
difference in adenoma detection rate for male patients (30%) and female patients (20%)
that equals an OR of 1.71.[7] Increasing BMI was included as a predictor in almost every previ-
ous prediction model for adenoma detection[18,20,24,25] as is the case in our prediction
model.
A recent Asian study found a self-reported family history of colorectal adenomas to be
associated with an increased risk of adenoma detection.[36] Moreover, a family history of
advanced adenomas has been shown to increase the risk of advanced adenoma detection.[37]
However in the present study a family history of adenomas was not independently predictive
for adenoma detection. Interestingly a family history of CRC was not found to be an indepen-
dent predictor either, while a family history of CRC has been previously included in prediction
models for both adenoma[18,23–25] and advanced adenoma detection.[16–19,22,23]
Some possible predictors for adenoma detection that have been associated with (advanced)
adenoma detection or CRC development are not collected within the GIQuIC database. Smok-
ing was included in prediction models for adenoma detection.[18,23–25] Furthermore alcohol
consumption has been associated with the development of (advanced) adenomas,[38] and has
been included as independent predictor in two prediction models for advanced adenomas.
[21,22] Certain medication, such as aspirin has been associated with a decreased risk of CRC
development[39] and could therefore have possibly added to the discrimination between
patients with and without adenomas.[25] In our model ASA class, which is routinely assessed
to make sedation decisions, might function as a proxy for medical condition in general. Never-
theless, assignment of ASA-class might heavily depend on the assessor, and certain medical
conditions, if predictive, would be less prone to observer judgment and might be more specific.
Lastly, dietary components, e.g. dietary fibers have been associated with a decreased risk of
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colorectal adenoma development,[40] and fried food, picked food, white meat or green vegeta-
ble consumption were predictive of advanced adenoma detection in a Chinese population.[15]
However, dietary factor assessment in clinical practice might suffer from recall bias. These fac-
tors should be considered to be included as variables within ADR monitoring databases such as
GIQuIC, if addition of any of these predictors would improve prediction of adenoma detection.
The moderate discriminative ability of our patient-factor based prediction model for ade-
noma detection is in line with a recent study in which adjustment of the ADR for age, sex,
race/ethnicity, and family history of CRC did reduce the variability in ADRs but had only a
small effect on the differences of ADRs between physicians.[41] In another study excluding
different patient subgroups from ADR calculations changed ADRs substantially, but had only
a small effect on the ADR ranking among physicians[42] suggesting that factors, such as physi-
cian-related, procedural or technological factors, are likely to influence the ADR. A physician-
effect might also be part of the explanation of the ADR increase during the first ten years of the
German CRC screening program, because physicians who started to perform screening colo-
noscopy detected more adenomas compared to physicians who stopped performing colonos-
copies.[43] Unfortunately, no physician-factors were known in our study, therefore their
influence on the variation in ADR could not be assessed. Future identification of modifiable
physician-factors next to for example withdrawal time could create opportunities for further
quality improvement in colonoscopy.
In this study, to the best of our knowledge, we describe the first prediction model for ade-
noma detection in a screening and surveillance population and its application to compare the
predicted proportion of patients with1 adenoma to the individual physician’s and center’s
observed ADRs. The study is strengthened by the prospective data collection. The large sample
size decreased the risk of model overfitting, which was further decreased by the internal and
geographical validation, however, a full external validation is still preferable before the model
would be widely applied.
Our study also has some limitations. Firstly, although handled in the most appropriate way
with multiple imputations, the substantial proportion of missing data on BMI might have
influenced our results. Moreover, data on race and ethnicity was possibly missing not at ran-
dom and could therefore not be handled with multiple imputation. Data on smoking status
was unknown for all patients. Secondly, the race and ethnicity sub classification was based on
the possibilities within the GIQuIC form; therefore we could for example not specify whether
Asian patients originally came from Asian countries with a low or high colorectal adenoma
prevalence. Thirdly, due to the design of data collection the pathologists could not be blinded
for all predictors during histology assessment. Fourthly, the number of patients who under-
went surveillance colonoscopy earlier or later than recommended is unknown. This could
have influenced the ADR in the surveillance group, however compared to screening colonos-
copy more patients with1 adenoma were detected during surveillance colonoscopy in the
present study. Lastly, since adenoma detection is not considered to be perfect with reported
per adenoma miss rates up to 20% of all adenomas,[44] the reference standard for detection,
i.e. colonoscopy, is not perfect. If the performing physician or procedural factors are truly
influencing the adenoma detection per patient, the outcome assessment might have been
biased. Unfortunately, it is not possible to determine to what extent this has influenced the per-
formance of our model and the selection of predictors.
Conclusions
We developed and validated a prediction model for colorectal adenoma detection in a screen-
ing and surveillance population based on patient-related predictors, i.e. age, sex, BMI, ASA
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class, surveillance as indication, and Hispanic or Latino ethnicity, with a modest discriminative
ability. Additional patient-related predictors that were not included in the database, e.g. smok-
ing, alcohol use, medication and medical history, could possibly have added to the model per-
formance. However, these data suggest that variation in ADR between physicians could likely
be due to a combination of patient-related and other factors, e.g. physician, procedural or tech-
nical issues. These data also suggest that a low individual physician’s ADR, can only partially
be explained by patient mix, and efforts to improve ADR to meet current guidelines should be
pursued.
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